|74.90||-0.6100||-0.81%||Vol 1.00M||1Y Perf -9.28%|
|May 13th, 2022 16:00 DELAYED|
|- -||0.70 0.93%|
|Target Price||87.42||Analyst Rating||Moderate Buy 2.00|
|Potential %||16.72||Finscreener Ranking||★★★★+ 56.08|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 59.53|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 77.58|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||49.30||Earnings Rating||Neutral|
|Market Cap||16.59B||Earnings Date||3rd May 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.34|
|EPS Growth Next 5 Years %||36.00|
|Avg. Weekly Volume||1.46M|
|Avg. Monthly Volume||1.47M|
|Avg. Quarterly Volume||1.51M|
Incyte Corporation (NASDAQ: INCY) stock closed at 74.9 per share at the end of the most recent trading day (a -0.81% change compared to the prior day closing price) with a volume of 1.00M shares and market capitalization of 16.59B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1773 people. Incyte Corporation CEO is Herve Hoppenot.
The one-year performance of Incyte Corporation stock is -9.28%, while year-to-date (YTD) performance is 2.04%. INCY stock has a five-year performance of -34.98%. Its 52-week range is between 61.91 and 88.26, which gives INCY stock a 52-week price range ratio of 49.30%
Incyte Corporation currently has a PE ratio of 17.90, a price-to-book (PB) ratio of 4.31, a price-to-sale (PS) ratio of 5.17, a price to cashflow ratio of 22.00, a PEG ratio of 2.32, a ROA of 21.92%, a ROC of 27.97% and a ROE of 28.98%. The company’s profit margin is 29.77%, its EBITDA margin is 20.40%, and its revenue ttm is $3.11 Billion , which makes it $14.06 revenue per share.
Of the last four earnings reports from Incyte Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.34 for the next earnings report. Incyte Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Incyte Corporation is Moderate Buy (2), with a target price of $87.42, which is +16.72% compared to the current price. The earnings rating for Incyte Corporation stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Incyte Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Incyte Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.64, ATR14 : 2.44, CCI20 : -43.36, Chaikin Money Flow : -0.04, MACD : -0.73, Money Flow Index : 48.04, ROC : 0.63, RSI : 45.72, STOCH (14,3) : 30.21, STOCH RSI : 0.72, UO : 42.83, Williams %R : -69.79), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Incyte Corporation in the last 12-months were: Barry P. Flannelly (Option Excercise at a value of $2 950 627), Barry P. Flannelly (Sold 43 993 shares of value $3 672 887 ), Dashyant Dhanak (Sold 1 569 shares of value $123 387 ), Jonathan Elliott Dickinson (Sold 7 375 shares of value $547 151 ), Maria E. Pasquale (Option Excercise at a value of $41 634), Paul Trower (Option Excercise at a value of $601 347), Paul Trower (Sold 8 214 shares of value $602 168 ), Paula J. Swain (Option Excercise at a value of $1 577 309), Paula J. Swain (Sold 20 189 shares of value $1 481 453 ), Vijay K. Iyengar (Sold 4 911 shares of value $384 482 ), Wendy L. Dixon (Option Excercise at a value of $1 465 000), Wendy L. Dixon (Sold 20 000 shares of value $441 000 ), Wenqing Yao (Sold 27 194 shares of value $2 321 551 )
Mon, 11 Apr 2022 16:05 GMT Incyte (INCY) Gets a Buy Rating from JMP Securities- TipRanks. All rights reserved.
Mon, 14 Mar 2022 16:15 GMT Incyte (INCY) Gets a Hold Rating from Mizuho Securities- TipRanks. All rights reserved.
Thu, 10 Feb 2022 05:35 GMT Incyte (INCY) Receives a Buy from JMP Securities- TipRanks. All rights reserved.
Thu, 10 Feb 2022 02:09 GMT Incyte (INCY) Receives a Hold from Stifel Nicolaus- TipRanks. All rights reserved.
Thu, 27 Jan 2022 05:15 GMT Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cortexyme (CRTX)- TipRanks. All rights reserved.
Tue, 18 Jan 2022 09:15 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Cytokinetics (CYTK)- TipRanks. All rights reserved.
Thu, 13 Jan 2022 06:45 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Incyte (INCY) and InflaRx (IFRX)- TipRanks. All rights reserved.
Thu, 06 Jan 2022 06:12 GMT What Does Incytes Newly Added Risk Factor Reveal- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.